GLAXOSMITHKLINE PHARMACEUTICALS
- Advice
- Hold
Glaxosmithkline Pharmaceuticals Share Price
Glaxosmithkline Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Glaxosmithkline Pharmaceuticals Investment Rating
-
Master Rating:
-
Glaxosmithkline Pharms. has an operating revenue of Rs. 3,380.52 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 24% is great, ROE of 63% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
- Indicator
- Jun 2022
- Mar 2022
- Dec 2021
- Sep 2021
- Jun 2021
- Mar 2021
- Oper Rev Qtr Cr
- 729
- 792
- 808
- 992
- 773
- 807
- Operating Expenses Qtr Cr
- 582
- 619
- 611
- 717
- 623
- 638
- Operating Profit Qtr Cr
- 148
- 173
- 197
- 274
- 151
- 169
- Depreciation Qtr Cr
- 16
- 15
- 18
- 18
- 18
- 18
- Interest Qtr Cr
- 1
- 0
- 1
- 0
- 1
- 1
- Tax Qtr Cr
- 44
- 262
- 33
- 69
- 44
- 48
- Net Profit Qtr Cr
- 119
- 1,218
- 150
- 203
- 120
- 13
Glaxosmithkline Pharmaceuticals Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 9
- Bearish Moving Average
- ___
- 7
- 20 Day
- 1454.51
- 50 Day
- 1478.95
- 100 Day
- 1517.71
- 200 Day
- 1588.1
- 20 Day
- 1444.28
- 50 Day
- 1485.49
- 100 Day
- 1526.15
- 200 Day
- 1589.11
Glaxosmithkline Pharmaceuticals Resistance and Support
- First Resistance
- 1491.15
- Second Resistance
- 1503.75
- Third Resistance
- 1520.5
- First Resistance
- 1461.8
- Second Resistance
- 1445.05
- Third Resistance
- 1432.45
- RSI
- 54.16
- MFI
- 63.03
- MACD Single Line
- -15.58
- MACD
- -7.07
Glaxosmithkline Pharmaceuticals Delivery and Volume
- Period
- NSE + BSE
Volume Avg - NSE + BSE
Delivery Volume Avg - NSE + BSE
Delivery Volume %
- Day
- 55,565
- 3,697,851
- 66.55
- Week
- 64,815
- 4,936,940
- 76.17
- 1 Month
- 81,456
- 5,538,217
- 67.99
- 6 Month
- 46,844
- 2,857,460
- 61
Glaxosmithkline Pharmaceuticals Result Highlights
GlaxoSmithKline Pharmaceuticals Synopsis
NSE-Medical-Diversified
Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3217.51 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2022. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.- Market Cap
- 24,956
- Sales
- 3,321
- Shares in Float
- 4.24
- No of funds
- 197
- Yield
- 2.04
- Book Value
- 9.32
- U/D Vol ratio
- 1.1
- LTDebt / Equity
- Alpha
- -0.03
- Beta
- 0.42
GlaxoSmithKline Pharmaceuticals
- Owner Name
- Jun-22
- Mar-22
- Dec-21
- Sep-21
- Promoters
- 75%
- 75%
- 75%
- Mutual Funds
- 4.06%
- 4.17%
- 4.18%
- Foreign Portfolio Investors
- 2.16%
- 2.18%
- 2.04%
- Financial Institutions/ Banks
- 0.02%
- 1.44%
- 1.43%
- Individual Investors
- 10.41%
- 10.41%
- 10.66%
- Others
- 8.35%
- 6.8%
- 6.69%
GlaxoSmithKline Pharmaceuticals Management
- Name
- Designation
- Ms. R S Karnad
- Chairperson
- Mr. Sridhar Venkatesh
- Managing Director
- Dr.(Ms.) S Maheshwari
- Director
- Mr. S Williams
- Director
- Mr. P V Bhide
- Director
- Mr. N Kaviratne
- Director
- Mr. A N Roy
- Director
- Mr. D Sundaram
- Director
- Mr. M Anand
- Director
- Mr. J Chandy
- Director
Glaxosmithkline Pharmaceuticals Forecast
Price Estimates
Glaxosmithkline Pharmaceuticals Corporate Action
- Date
- Purpose
- Remarks
- 2022-07-25
- Quarterly Results
- 2022-05-16
- Audited Results & Dividend
- 2022-02-07
- Quarterly Results
- 2021-10-29
- Quarterly Results
- 2021-07-26
- Quarterly Results
- Date
- Purpose
- Remarks
- 2022-07-08
- FINAL
- Rs.30.00 per share(300%)Dividend
- 2022-07-08
- SPECIAL
- Rs.60.00 per share(600%)Special Dividend
- 2021-07-20
- FINAL
- Rs.30.00 per share(300%)Dividend
GlaxoSmithKline Pharmaceuticals FAQs
What is Share Price of GlaxoSmithKline Pharmaceuticals ?
GlaxoSmithKline Pharmaceuticals share price is ₹1473 As on 20 August, 2022 | 08:14
What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹24956 Cr As on 20 August, 2022 | 08:14
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 14.7 As on 20 August, 2022 | 08:14
What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?
The PB ratio of GlaxoSmithKline Pharmaceuticals is 9.4 As on 20 August, 2022 | 08:14